Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 14, 2023 53.3% of pediatric patients treated with AB-101a achieved a 1-point decrease in IGA vs. 0% of those treated with vehicle. This outcome was also seen in 60% of…
Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection NEWS PROVIDED BY Alphyn Biologics Jul 14, 2023, 07:30 ET Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE, N.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics,…
Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 13, 2023, 19:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis Heather Raglin, Editor NEWS PROVIDED BY Alphyn Biologics July 11, 2023 Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon. Read the Dermatology Times article here. CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com…
Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Jul 10, 2023, 16:15 ET -Statistically significant improvements in IGA (Investigator Global Assessment) and EASI (Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body…
World Congress of Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 6, 2023, 10:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial NEWS PROVIDED BY Alphyn Biologics May 04, 2023, 07:30 ET Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target…
European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress NEWS PROVIDED BY Alphyn Biologics Apr 27, 2023, 07:30 ET ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase…
VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results NEWS PROVIDED BY Alphyn Biologics Mar 21, 2023 In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline. View the video here. CONTACTS Corporate: Neal Koller…